spacer
home > epc > autumn 2003 > driving patient compliance
PUBLICATIONS
European Pharmaceutical Contractor

Driving Patient Compliance

The Scope of the Problem

Non-compliance commonly refers to the failure of patients to take medicines in their prescribed manner. Recognised as a serious health care issue, studies show that patient non-compliance can range from 20-80 per cent depending on the type of treatment being taken (1). The problem of non-compliance is not a new one and has been investigated for several decades worldwide.

The Consequences

Patient non-compliance lessens the quality of health care and can lead to dangerous consequences for patients. In the US, it has been estimated that non-compliance causes 340 deaths per day and is responsible for 10-25 per cent of hospital and nursing home admissions. Patient non-compliance is taken so seriously in the US that the New York Times dubbed it the nation's 'other drug problem' (2).

In a recent study conducted by Dendrite's Analytika Division, based on an analysis of data from nearly half of the US retail chain and independent companies, it was discovered that 'fewer than one in four patients on a cholesterol-lowering therapy completes a full year of treatment' (3). For the pharma industry, this gap between compliance and persistence translates into vast amounts of lost revenue.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc

Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.


Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.


spacer
Pietro Bonacossa
spacer
spacer
spacer
Dr Faiz Kermani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement